Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1013. The purpose of this neoadjuvant and adjuvant study is to evaluate the efficacy and safety of Serplulimab and chemotherapy in treating resectable Non-Small Cell Lung Cancer(NSCLC). The study also intended to explore the immune function of tumor-draining lymph nodes during immunotherapy.

Timeline

Start

2023-03-15

Primary completion

2024-05-28

Completion

2025-09-01

Publications

• Fu F, Wu H, Deng C, Chen H, Huang Q, Yuan C, Ding X, Ye T, Zhou Y, Chen S, Sun Y, Zhang Y, Xiang J, Wang S, Li Y, Li B, Lu Y, Zhang Y, Hu H, Chen H. Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis. J Immunother Cancer. 2026 May 11;14(5):e014437. doi: 10.1136/jitc-2025-014437.

Drugs

Indications